Pseudomonas aeruginosa

Principles and Practice of Pediatric Infectious Diseases, Fourth Edition

Volumn , Issue , 2012, Pages 842-846.e2

  Prince, Alice S ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84967143928     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-2702-9.00157-4     Document Type: Chapter

References (45)

1. M Wu, T Guina, M Brittnacher, et al. (2005) The Pseudomonas aeruginosa proteome during anaerobic growth. J Bacteriol 187 8185-8190.
2. S Lory, M Merighi and M Hyodo (2009) Multiple activities of c-di-GMP in Pseudomonas aeruginosa. Nucleic Acids Symp Ser (Oxf) 53 51-52.
3. TL Yahr and EP Greenberg (2004) The genetic basis for the commitment to chronic versus acute infection in Pseudomonas aeruginosa. Mol Cell 16 497-498.
4. YQ O’Malley, KJ Reszka, DR Spitz, et al. (2004) Pseudomonas aeruginosa pyocyanin directly oxidizes glutathione and decreases its levels in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 287 L94-103.
5. RF Jacobs, RE McCarthy and JM Elser (1989) Pseudomonas osteochondritis complicating puncture wounds of the foot in children: a 10-year evaluation. J Infect Dis 160 657-661.
6. MJ Chusid and SM Hillmann (1987) Community-acquired Pseudomonas sepsis in previously healthy infants. Pediatr Infect Dis J 6 681-684.
7. RT Sadikot, TS Blackwell, JW Christman and AS Prince (2005) Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 171 1209-1223.
8. G Grisaru-Soen, L Lerner-Geva, N Keller, et al. (2000) Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors. Pediatr Infect Dis J 19 959-963.
9. E DiMango, HJ Zar, R Bryan and A Prince (1995) Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 96 2204-2210.
10. PJ Dubin and JK Kolls (2007) IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 292 L519-528.
11. S Saba, G Soong, S Greenberg and A Prince (2002) Bacterial stimulation of epithelial G-CSF and GM-CSF expression promotes PMN survival in CF airways. Am J Respir Cell Mol Biol 27 561-567.
12. JD Li, AF Dohrman, M Gallup, et al. (1997) Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc Natl Acad Sci USA 94 967-972.
13. AR Hauser (2009) The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7 654-665.
14. H Sato, JB Feix and DW Frank (2006) Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. Biochemistry 45 10368-10375.
15. CM Shaver and AR Hauser (2004) Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 72 6969-6977.
16. SM Zughaier, HC Ryley and SK Jackson (1999) Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes. Infect Immun 67 1505-1507.
17. Z Zhang, JP Louboutin, DJ Weiner, et al. (2005) Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by toll-like receptor 5. Infect Immun 73 7151-7160.
18. PW Park, GB Pier, MT Hinkes and M Bernfield (2001) Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence. Nature 411 98-102.
19. YS Lopez-Boado, CL Wilson and WC Parks (2001) Regulation of matrilysin expression in airway epithelial cells by Pseudomonas aeruginosa flagellin. J Biol Chem 276 41417-41423.
20. C Geary, H Akinbi, T Korfhagen, et al. (2005) Increased susceptibility of purinergic receptor-deficient mice to lung infection with Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 289 L890-895.
21. LM Cobb, JC Mychaleckyj, DJ Wozniak and YS Lopez-Boado (2004) Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J Immunol 173 5659-5670.
22. PK Singh, AL Schaefer, MR Parsek, et al. (2000) Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 762-764.
23. RC Boucher (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 23 146-158.
24. SS Yoon, RF Hennigan, GM Hilliard, et al. (2002) Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 3 593-603.
25. JW Costerton, PS Stewart and EP Greenberg (1999) Bacterial biofilms: a common cause of persistent infections. Science 284 1318-1322.
26. DM Ramsey and DJ Wozniak (2005) Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis. Mol Microbiol 56 309-322.
27. AN Maniatis, C Karkavitsas, NA Maniatis, et al. (1995) Pseudomonas aeruginosa folliculitis due to non-O:11 serogroups: acquisition through use of contaminated synthetic sponges. Clin Infect Dis 21 437-439.
28. AR Marra, GM Bearman, RP Wenzel and MB Edmond (2005) Comparison of the systemic inflammatory response syndrome between monomicrobial and polymicrobial Pseudomonas aeruginosa nosocomial bloodstream infections. BMC Infect Dis 5 94.
29. M Foca, K Jakob, S Whittier, et al. (2000) Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N Engl J Med 343 695-700.
30. JL Veesenmeyer, AR Hauser, T Lisboa and J Rello (2009) Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 37 1777-1786.
31. L Wiehlmann, G Wagner, N Cramer, et al. (2007) Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 104 8101-8106.
32. A Bragonzi, M Paroni, A Nonis, et al. (2009) Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180 138-145.
33. D Landman, S Bratu, M Alam and J Quale (2005) Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 55 954-957.
34. A Oliver, BR Levin, C Juan, et al. (2004) Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 48 4226-4233.
35. JA Karlowsky, ME Jones, C Thornsberry, et al. (2005) Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001–2003 tracking resistance in the United States today surveillance studies. Clin Infect Dis 40(Suppl 2), S89-S98.
36. K Poole and R Srikumar (2001) Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 1 59-71.
37. A Deplano, O Denis, L Poirel, et al. (2005) Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J Clin Microbiol 43 1198-1204.
38. TP Lodise Jr, N Patel, A Kwa, et al. (2007) Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51 3510-3515.
39. CM Odio, JR Puig, JM Feris, et al. (1999) Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 18 581-590.
40. A Wong-Beringer, P Beringer and MA Lovett (1997) Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin. Clin Infect Dis 25 936-937.
41. JL Axelrod, JC Newton, RM Klein, et al. (1987) Penetration of imipenem into human aqueous and vitreous humor. Am J Ophthalmol 104 649-653.
42. SK Chuck, SR Raber, KA Rodvold and D Areff (2000) National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 30 433-439.
43. VH Tam, AN Schilling, G Vo, et al. (2005) Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49 3624-3630.
44. AL Kwa, C Loh, JG Low, et al. (2005) Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41 754-757.
45. G Doring, C Meisner and M Stern (2007) A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 104 11020-11025.